Baxter's HyQ Long-term Data for Clinical Study on PI

Baxter International Inc. declared the presentation of excess long-term figures helping the clinical profile of HyQ, its investigational combination product in order to use in affected individuals with primary immunodeficiencies (PI).

The firm also launched HyQvia [Immune Globulin Infusion 10% (Human) having Recombinant Human Hyaluronidase], because the submitted trusted brand name for the investigational product, formerly referred to as HyQ. Posters and oral presentations with regard to the HyQvia clinical program will probably be given throughout the 2012 American Academy of Allergy, Asthma and Immunology (AAAAI) Every year meeting in Orlando.

Prof. Hartmut J Ehrlich, M.D., vice chairman of global research and development in Baxter's BioScience Company said that, "The HyQvia clinical plan continues to be focused on acquiring long-term data this particular new facilitated subcutaneous immunoglobulin session, which includes safety, efficacy, tolerability, and pharmacokinetic files." This documentation can be used to inform physicians in producing the optimal treatment choice for the affected individuals.

Selected Study Figures of Concern

Security and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a very Phase III Addition Study in Sufferers Having Primary Immunodeficiency Disorder.

Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Applied Intravenously (IGIV), Subcutaneously (IGSC) or Made simple Subcutaneously with Recombinant Human Hyaluronidase (IGHy) within a Subset of Individuals having Primary Immunodeficiency Problem.

Tolerability and Performance of Facilitated-Subcutaneous Infusion of Protected Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) inside a Subset of Survey Sufferers having Primary Immunodeficiency Disorder